These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31691472)

  • 1. Efficacy and safety of MYL-1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study.
    Blevins TC; Barve A; Raiter Y; Aubonnet P; Athalye S; Sun B; Muniz R
    Diabetes Obes Metab; 2020 Mar; 22(3):365-372. PubMed ID: 31691472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of MYL-1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study.
    Blevins TC; Barve A; Sun B; Raiter Y; Aubonnet P; Muniz R; Athalye S; Ankersen M
    Diabetes Obes Metab; 2019 Jan; 21(1):129-135. PubMed ID: 30112792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study.
    Blevins TC; Barve A; Sun B; Ankersen M
    Diabetes Obes Metab; 2018 Aug; 20(8):1944-1950. PubMed ID: 29656504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies.
    Sun B; Sengupta N; Rao A; Donnelly C; Waichale V; Roy AS; Ramaswamy S; Pathak D; Bowsher RR; Raiter Y; Aubonnet P; Barve A
    BMC Endocr Disord; 2021 Jun; 21(1):129. PubMed ID: 34174848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog
    Blevins TC; Raiter Y; Sun B; Donnelly C; Shapiro R; Chullikana A; Rao A; Vashishta L; Ranganna G; Barve A
    BioDrugs; 2022 Nov; 36(6):761-772. PubMed ID: 36114990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL-1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus.
    Heise T; Donnelly C; Barve A; Aubonnet P
    Diabetes Obes Metab; 2020 Apr; 22(4):521-529. PubMed ID: 31724253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physicochemical and functional characterization of MYL-1501D, a proposed biosimilar to insulin glargine.
    Goyal P; Pai HV; Kodali P; Vats B; Vajpai N; Annegowda S; Mane K; Mohan S; Saxena S; Veerabhadraia AB; Palande M; Nair PS; More DC; Karudumpa UR; Jyothirmai K; Bhattacharya A; Almeida F; Khyade SG; Gouda S; Ranayhossaini DJ; Moole PR; Smith JP; Barve A; Melarkode R; Ullanat R
    PLoS One; 2021; 16(6):e0253168. PubMed ID: 34133466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.
    Christofides EA; Puente O; Norwood P; Denham D; Maheshwari H; Lillestol M; Hart T; Nakhle S; Chadha A; Fitz-Patrick D; Sugimoto D; Soufer J; Young D; Warren M; Huffman D; Reed J; Bays H; Arora S; Rizzardi B; Tidman R; Rendell M; Johnson KA
    Diabetes Obes Metab; 2024 Jun; 26(6):2412-2421. PubMed ID: 38558508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study.
    Garg SK; Wernicke-Panten K; Rojeski M; Pierre S; Kirchhein Y; Jedynasty K
    Diabetes Technol Ther; 2017 Sep; 19(9):516-526. PubMed ID: 28722480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.
    Home PD; Lam RLH; Carofano WL; Golm GT; Eldor R; Crutchlow MF; Marcos MC; Rosenstock J; Hollander PA; Gallwitz B
    Diabetes Obes Metab; 2018 Sep; 20(9):2220-2228. PubMed ID: 29766635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial.
    Hollander PA; Carofano WL; Lam RLH; Golm GT; Eldor R; Crutchlow MF; Marcos MC; Rendell MS; Home PD; Gallwitz B; Rosenstock J
    Diabetes Obes Metab; 2018 Sep; 20(9):2229-2237. PubMed ID: 29761615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial.
    Garg SK; Wernicke-Panten K; Wardecki M; Kramer D; Delalande F; Franek E; Sadeharju K; Monchamp T; Miossec P; Mukherjee B; Shah VN
    Diabetes Technol Ther; 2020 Jul; 22(7):516-526. PubMed ID: 32068436
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus®) in Chinese patients with type 1 diabetes: A phase III, randomized, controlled trial.
    Yan X; Jiang S; Lou Y; Zhou Z
    Diabetes Obes Metab; 2021 Oct; 23(10):2226-2233. PubMed ID: 34121308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1).
    Garg SK; Wernicke-Panten K; Wardecki M; Kramer D; Delalande F; Franek E; Sadeharju K; Monchamp T; Mukherjee B; Shah VN
    Diabetes Technol Ther; 2020 Feb; 22(2):85-95. PubMed ID: 31804851
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open-label, controlled trial.
    Feng W; Chen W; Jiang S; Du L; Zhu D
    Diabetes Obes Metab; 2021 Aug; 23(8):1786-1794. PubMed ID: 33783964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment satisfaction, safety, and effectiveness of biosimilar insulin glargine is comparable in patients with type 2 diabetes mellitus after switching from insulin glargine or insulin degludec: a post-marketing safety study.
    Taki K; Koyanagi M; Nagaoka S; Shingaki T
    Curr Med Res Opin; 2020 Dec; 36(12):1975-1983. PubMed ID: 33030354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6-17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial.
    Danne T; Tamborlane WV; Malievsky OA; Franco DR; Kawamura T; Demissie M; Niemoeller E; Goyeau H; Wardecki M; Battelino T
    Diabetes Care; 2020 Jul; 43(7):1512-1519. PubMed ID: 32430458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study.
    Blevins TC; Dahl D; Rosenstock J; Ilag LL; Huster WJ; Zielonka JS; Pollom RK; Prince MJ
    Diabetes Obes Metab; 2015 Aug; 17(8):726-33. PubMed ID: 25974640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine.
    Hadjiyianni I; Dahl D; Lacaya LB; Pollom RK; Chang CL; Ilag LL
    Diabetes Obes Metab; 2016 Apr; 18(4):425-9. PubMed ID: 26749289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.